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Abstract
BACKGROUND—The causative agents for the current national outbreak of electronic-cigarette, 
or vaping, product use-associated lung injury (EVALI) have not been established. Detection of 
toxicants in bronchoalveolar-Iavage (BAL) fluid from patients with EVALI can provide direct 
information on exposure within the lung.
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METHODS—BAL fluids were collected from 51 patients with EVALI in 16 states and from 99 
healthy participants who were part of an ongoing study of smoking involving nonsmokers, 
exclusive users of e-cigarettes or vaping products, and exclusive cigarette smokers that was 
initiated in 2015. Using the BAL fluid, we performed isotope dilution mass spectrometry to 
measure several priority toxicants: vitamin E acetate, plant oils, medium-chain triglyceride oil, 
coconut oil, petroleum distillates, and diluent terpenes.
RESULTS—State and local health departments assigned EVALI case status as confirmed for 25 
patients and as probable for 26 patients. Vitamin E acetate was identified in BAL fluid obtained 
from 48 of 51 case patients (94%) in 16 states but not in such fluid obtained from the healthy 
comparator group. No other priority toxicants were found in BAL fluid from the case patients or 
the comparator group, except for coconut oil and limonene, which were found in 1 patient each. 
Among the case patients for whom laboratory or epidemiologic data were available, 47 of 50 
(94%) had detectable tetrahydrocannabinol (THC) or its metabolites in BAL fluid or had reported 
vaping THC products in the 90 days before the onset of illness. Nicotine or its metabolites were 
detected in 30 of 47 of the case patients (64%).
CONCLUSIONS—Vitamin E acetate was associated with EVALI in a convenience sample of 51 
patients in 16 states across the United States. (Funded by the National Cancer Institute and others.)
AS OF DECEMBER 12, 2019, THE ONGOING national outbreak of electronic-cigarette, 
or vaping, product use-associated lung injury (EVALI) has affected more than 2400 
hospitalized patients across all 50 states, the District of Columbia, the U.S. Virgin Islands, 
and Puerto Rico. In addition, 52 deaths had been reported in 25 states and the District of 
Columbia.1 Most patients with EVALI (78%) have been young than 35 years of age and 
have reported a gradual onset of symptoms — including respiratory (95%), constitutional 
(85%), and gastrointestinal (77%) symptoms — over days to weeks.2 Nearly half the 
patients (47%) required intensive care to treat respiratory failure.2 Most patients have 
reported the use of e-cigarette products containing tetrahydrocannabinol (THC).3 Radio-
graphic findings may not be apparent on presentation, but such patients commonly are found 
to have basilar-predominant consolidation and ground-glass opacity.4 Histopathological 
features of acute lung injury have been described, including diffuse alveolar damage, acute 
fibrinous pneumonitis, and organizing pneumonia.5
EVALI cases were first reported to the Centers for Disease Control and Prevention (CDC) in 
August 2019 and rapidly increased in number thereafter, which suggests new or increased 
exposure to one or more toxicants from the use of e-cigarette products. The initial laboratory 
strategy to help determine the cause of EVALI was to analyze product fluids associated with 
case patients to detect toxicants in these products that could account for the lung injury. In 
September, the New York State Department of Health Wadsworth Center Laboratory 
reported results for 34 persons who used THC-containing e-cigarette products and had 
pulmonary illness.6 Many of these patients had used multiple products; however, each one 
had used at least one THC-containing product that tested positive for vitamin E acetate, a 
chemical that is sometimes used as a thickening agent in illicit THC-containing products. 
The Food and Drug Administration (FDA) also analyzed product fluids for vitamin E 
acetate, diluents, metals, and other selected chemicals. Patients with EVALI have commonly 
used multiple tobacco and cannabis products.7 FDA investigators analyzed multiple product 
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samples for each patient, some of which may or may not have contained a causative agent. 
Among case associated THC-containing product samples, investigators found vitamin E 
acetate in 49% of the samples and at least one other potential toxicant (e.g., medium-chain 
triglycerides) in 24% of the samples.8 Furthermore, trade websites9–11 have reported the 
addition of various diluents (e.g., vitamin E acetate and medium-chain triglycerides) to 
THC-containing products to enhance their quality and appearance, provide desirable aroma 
or taste, and lower product cost.
As an expansion of the laboratory strategy for the lung-injury response, the CDC, in 
consultation with the FDA, began testing for harmful substances in bronchoalveolar-lavage 
(BAL) fluid obtained from patients with EVALI. The CDC put primary emphasis on the 
analysis of BAL fluid because this approach could detect harmful substances at the 
presumed site of the lung injury. In collaboration with state health departments, the CDC 
obtained BAL fluid samples from 29 patients with EVALI in 10 states, with analysis 
showing the presence of vitamin E acetate in all 29 samples.12 This study extends that work 
by analyzing samples from 51 patients with EVALI in 16 states along with samples obtained 
from 99 healthy participants in a smoking-related study that included never smokers, 
exclusive e-cigarette users, and exclusive cigarette smokers.
METHODS
CASE DEFINITIONS
All case-associated BAL fluid samples were obtained from patients who met EVALI case 
definitions of the CDC, as determined by state or local health officials (Table 1).13
BIOSPECIMEN COLLECTION FROM CASE AND COMPARATOR PARTICIPANTS
EVALI Case Patients—BAL fluid was obtained by clinical teams caring for hospitalized 
patients. The decision to obtain BAL fluid was made by the clinical team on a case-by-case 
basis to guide clinical management decisions. The CDC requested the assistance of state 
health departments in acquiring BAL fluid samples. If a patient qualified as having a 
probable or confirmed diagnosis of EVALI, then BAL fluid was accepted by the CDC for 
analysis. No other inclusion or exclusion criteria were applied.
The small volumes of BAL fluid in some samples required prioritizing analyses. Vitamin E 
acetate was prioritized first, followed by dipalmitoylphosphatidylcholine (DPPC), 
cannabinoids, and then other toxicants. Insufficient clinical data were available to estimate 
the time between the last use of an e-cigarette product and the bronchoscopy to obtain BAL 
fluid. Sample collection was conducted according to the routine clinical processes at each 
institution and was not standardized. Samples were refrigerated or frozen after collection 
and shipped to the CDC on dry ice. Human-subjects research review was conducted by the 
CDC, which determined that this information collection did not meet the regulatory 
definition of research under 45 CFR 46.102(d) and was therefore determined to be a 
nonresearch public health response activity.
Healthy Comparator Group—BAL fluid had been previously obtained from 99 
participants that included nonusers, current exclusive users of nicotine-containing e-cigarette 
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products, and current exclusive cigarette smokers recruited through local media and 
participant registries at Ohio State University14,15 as part of a tobacco-product study 
unrelated to the ongoing EVALI investigation. The participants were between the ages of 21 
and 45 years and had no major clinical illness or increased risk from bronchoscopy. 
Inclusion and exclusion criteria for the 52 nonusers, the 18 exclusive users of nicotine-
containing e-cigarette products, and the 29 exclusive cigarette smokers have been reported 
previously.15 The negative smoking status for both the nonusers and users of e-cigarette 
products was confirmed biochemically by urinary anatabine testing.15 After collection, BAL 
fluids were transported to the laboratory on wet ice and processed within 30 minutes by 
centrifugation; cell pellets and supernatant were immediately placed in storage at −80°C.
All the participants provided written informed consent before participation. The tobacco-
product study involving healthy participants was approved by the institutional review board 
at Ohio State University.16
LABORATORY ANALYSIS
Investigators at the CDC established a list of priority toxicants to measure in BAL fluid: 
vitamin E acetate, plant oils (identified by measuring long-chain triglycerides), medium-
chain triglyceride oil, coconut oil (identified by measuring medium-chain triglycerides), 
petroleum distillates, and diluent terpenes (including limonene). For these toxicants in BAL 
fluid, the CDC developed and validated analytic methods that were evaluated for accuracy, 
precision, analytic sensitivity, and analytic specificity. These methods used isotope dilution 
mass spectrometry and provided results that met or exceeded the quality criteria of the 
Clinical Laboratory Improvement Amendments.
The analytic limit of detection (LOD) was calculated on the basis of repeated measures to 
estimate the standard deviation at zero concentration.17 Results higher than the LOD are 
reported as positive, and results lower than the LOD are reported as negative. The methods 
to measure each of the potential toxicants of concern — along with THC and nicotine parent 
compounds and metabolites and DPPC — are described in Table S1 in the Supplementary 
Appendix, available with the full text of this article at NEJM.org.18–20 All case and 
comparator samples of BAL fluid had detectable levels of DPPC, the main phospholipid of 
lung surfactant; DPPC was used as a marker to indicate that the BAL fluid contained 
pulmonary epithelial-lining fluid and thus was considered to be an adequate sample for 
testing.
DATA ANALYSIS
Results are presented as percentages of persons in whom BAL fluid samples tested positive 
for the measured toxicant or metabolite biomarker. Because of the limited volume of BAL 
fluid, results for all analytes were not available for all participants. Since the analysis of 
vitamin E acetate was prioritized, results regarding vitamin E acetate are reported for all the 
participants. Denominators reflect the actual number of participants for whom samples were 
tested for each analyte.
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RESULTS
From August through December 2019, public health laboratories and health departments in 
16 states provided BAL fluid samples obtained from 51 patients, including those in Arizona 
(2), Arkansas (2), California (4), Connecticut (1), Hawaii (1), Illinois (12), Indiana (1), 
Maryland (4), Michigan (2), Minnesota (5), Missouri (1), North Carolina (2), Texas (2), 
Utah (3), West Virginia (1), and Wisconsin (8). BAL fluid was acquired from 3 patients with 
EVALI who later died.
The age and sex of the 51 patients for whom BAL fluid was available were consistent with 
national data regarding patients with EVALI.7 The median age of the patients was 23 years, 
and 69% were male (Table 2). Among the patients for whom information was available, 77% 
reported the use of THC-containing products, 67% reported the use of nicotine-containing 
products, and 51% reported the use of both types of products. Health departments assigned 
and reported case status for all patients; of these patients, 25 had been classified as having 
confirmed EVALI and 26 as having probable EVALI.
Samples from healthy study participants were collected from 2016 through 2019, with 90 of 
the 99 samples obtained before 2019. The mean (±SD) age in years was 25.4±3.6 for 
nonusers, 26.5±2.7 for exclusive e-cigarette users, and 27.3±4.9 for exclusive cigarette 
smokers. Men made up 37%, 67%, and 76%, respectively, of the subgroups. Among the 
healthy participants, urine THC biomarkers were positive in 25.6%, whereas BAL fluid 
THC biomarkers were positive in 5.1%. The higher sensitivity of urine than of BAL fluid for 
the detection of THC biomarkers has been reported previously.21 The prevalence of positive 
urine THC biomarkers was highest among the participants who reported exclusive cigarette 
smoking (13 of 23 [57%]). Nicotine or its metabolites were detected in 52% of BAL fluids 
from the healthy participants. All the BAL fluid samples from this group were negative for 
all priority toxicants: vitamin E acetate, plant oils, medium-chain triglyceride oil, coconut 
oil, petroleum distillates, and diluent terpenes.
Among the patients with EVALI, vitamin E acetate was detected in BAL fluid samples from 
48 of 51 (94%) (Table 3). In 1 patient, BAL fluid had detectable levels of coconut oil in 
addition to vitamin E acetate; in another patient, BAL fluid contained limonene (a diluent 
terpene) with no detectable vitamin E acetate or THC. Samples from all the other patients 
were negative for the other priority toxicants: plant oils, medium-chain triglyceride oil, 
coconut oil, petroleum distillates, and diluent terpenes. Table 4 provides a clinical 
description of the 3 patients with EVALI who had no detectable vitamin E acetate; all of 
these 3 patients were classified as having probable cases. THC or its metabolites were 
detected in BAL fluid samples from 40 of 47 patients (85%) with EVALI. A total of 9 of 11 
patients who reported no use of THC-containing e-cigarette products in the 90 days before 
the onset of illness had detectable THC or its metabolites in their BAL fluid. Among the 
patients who had available laboratory data or who reported product use, 47 of 50 (94%) had 
detectable THC or its metabolites in BAL fluid or reported vaping THC products in the 90 
days before the onset of illness. Nicotine or its metabolites were detected in 30 of 47 (64%) 
BAL fluid samples from case patients.
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DISCUSSION
In our study, the detection of vitamin E acetate in BAL fluid in most of the patients with 
EVALI provides evidence that e-cigarette, or vaping, products can deliver vitamin E acetate 
to respiratory epithelial-lining fluid, the presumed site of injury in the lung. In this 
convenience sample, the finding that 48 of 51 patients with lung injury had vitamin E acetate 
in their BAL fluid is noteworthy. By contrast, vitamin E acetate was not detected in any BAL 
fluid collected from 99 healthy participants, including 18 e-cigarette users. In addition, the 
absence of other toxicants (plant oils, medium-chain triglyceride oil, coconut oil, petroleum 
distillates, and diluent terpenes) in BAL fluids from nearly all patients with EVALI provides 
evidence against the role of any of these toxicants as a primary cause of EVALI. Whether 
limonene or coconut oil (found in the BAL fluid of 1 patient each) may have some 
toxicologic effect is unclear.
Vitamin E acetate was not detected in the BAL fluid obtained from three patients with 
probable EVALI. Since EVALI is a diagnosis of exclusion for which there is no 
confirmatory diagnostic test, we could not confirm case status for these three patients. The 
EVALI case definition is intentionally sensitive, which raises the likelihood that a patient’s 
illness could be misattributed to EVALI. The alternative diagnoses that are listed in Table 4 
could reasonably explain the lung injury in these patients. Of note, the two patients who 
were successfully interviewed by public health officials denied vaping THC products. 
Reliable information on the time interval from the last use of an e-cigarette product until 
bronchoscopy is not available, so we cannot assess the likelihood that vitamin E acetate may 
have already been cleared from the lung in these patients. The detection of vitamin E acetate 
and other oils can be impaired by inadequate mixing of BAL fluid. Because BAL fluid was 
collected and processed in the local hospital setting according to its own protocols, we could 
not confirm that samples were adequately mixed. Patient 2 (as described in Table 4) reported 
the daily use of flavored nicotine products and had positive results for limonene (which is 
found in flavored nicotine solutions) in BAL fluid. Whether limonene has a toxicologic 
effect is unclear.22,23
Vitamin E acetate is commonly used as a dietary supplement and in skin creams. It is 
common in multivitamins and is enzymatically cleaved to vitamin E during absorption.24,25 
Although the ingestion and dermal application of vitamin E acetate have not generally been 
associated with adverse health effects, the safety of inhaling vitamin E acetate has received 
little attention. Vitamin E acetate is the ester of vitamin E (a-tocopherol) and acetic acid. The 
structure shows a long aliphatic tail that can penetrate a layer of surfactant to align the 
molecule in parallel with phospholipids26 (Fig. S1). Phosphatidylcholines undergo transition 
from a gel to a liquid crystalline phase when exposed to increasing amounts of tocopherols, 
such as vitamin E acetate.26,27 Transitioning to a liquid crystalline phase25 would cause the 
surfactant to lose its ability to maintain the surface tension that is necessary to support 
respiration in the lung,26,28,29 thus providing a possible mechanism by which vitamin E 
acetate could cause respiratory dysfunction.
Another potential harmful effect of vitamin E acetate that may contribute to lung injury 
occurs when it is heated in e-cigarette products. Heating vitamin E acetate in these devices 
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may create ketene by splitting off the acetate group from some or all of the vitamin E 
acetate.30 Ketene is a reactive compound that has the potential to be a lung irritant, 
depending on concentration. The CDC is currently examining ways to quantify ketene and 
its effects in BAL fluid.
Data that have been reported to date indicate that vitamin E acetate in the supply of THC-
containing products and use among patients with EVALI aligns with the timing of the 2019 
EVALI outbreak. In Minnesota, 10 of 10 products seized by law enforcement during 2018, 
before the EVALI outbreak, did not contain vitamin E acetate, whereas 20 of 20 THC-
containing products seized by law enforcement during September 2019, at the peak of the 
outbreak, contained vitamin E acetate.31 This finding is consistent with laboratory 
measurements and trade websites, which suggests that the addition of vitamin E acetate to 
product fluid began to appear in the illicit market in late 2018 or early 2019 and gained 
popularity in 2019.
Pure THC oil has a viscosity like that of vitamin E acetate. Cutting THC oil with vitamin E 
acetate has been reported to be common in the illicit market.9–11 The FDA reports that most 
case-associated THC product fluids contain vitamin E acetate, at an average concentration of 
50% by weight, ranging from 23 to 88%.8 By contrast, the FDA detected no vitamin E 
acetate in 197 case-associated nicotine products analyzed to date. The viscosity of vitamin E 
acetate makes it undesirable as an additive to nicotine solutions; the propylene glycol and 
vegetable glycerin in nicotine solutions create a fluid with a much lower viscosity than that 
of vitamin E acetate.
Additional studies (including studies in animals) are in progress to examine the respiratory 
effects of inhaling aerosolized vitamin E acetate and will provide information on whether 
vitamin E acetate in isolation causes lung injury.32 Research analyzing the aerosol and gases 
generated by case-associated product fluids is ongoing.
This study has several limitations. First, it is possible that vitamin E acetate may be a marker 
for exposure to alternative toxicants. Such an alternative toxicant would need to meet at least 
three criteria: correlate with the presence of vitamin E acetate in BAL fluid, be in 
widespread use across the United States, and have been added to THC product fluids in 2019 
or substantially increased in concentration in 2019 to match the timing of the outbreak. We 
have not been able to identify a toxicant that meets these three requirements but continue to 
study this possibility. Second, the contribution to injury of aerosol constituents formed from 
the heating of vitamin E acetate, especially at higher voltages, requires further examination. 
Until aerosolized constituents are better characterized, it is possible that one or more of them 
could act alone or synergistically with other compounds such as vitamin E acetate to 
increase the risk of EVALI. Third, sample collection was performed as part of routine 
clinical care and thus was not standardized. Fourth, the timing and burden of exposure to the 
potential toxicants in relation to the BAL sample acquisition could not be assessed. Finally, 
this study reports data for case patients and healthy comparators from an independent cross-
sectional study, which limits insights because samples were collected at a single point in 
time, and the possibility of unknown confounding remains.
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Vitamin E acetate may play a role in EVALI, a conclusion supported by the high detection 
rate of vitamin E acetate in BAL fluid from case patients who live in 16 states across the 
United States and the absence of vitamin E acetate in samples obtained from a healthy 
comparison group, by the absence of other priority toxicants in nearly all BAL fluid samples 
from case patients, by a biologically plausible mechanism for lung injury associated with 
vitamin E acetate, and by the temporal alignment between EVALI and the use of vitamin E 
acetate in the illicit marketplace. Results from studies in animals can provide information on 
whether exposure to vitamin E acetate alone can directly cause the lung injury seen in 
patients with EVALI.
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Table 1.
Case Definitions for Patients with EVALI.*
Confirmed Case Probable Case
Use of e-cigarette (“vaping”) or dabbing† during the 
90 days before symptom onset AND
Use of e-cigarette (“vaping”) or dabbing|† during the 90 days before symptom onset 
AND
Presence of pulmonary infiltrate, such as opacities, 
on chest radiography or ground-glass opacities on 
chest computed tomography AND
Presence of pulmonary infiltrate, such as opacities, on chest radiography or ground-
glass opacities on chest computed tomography AND
A negative respiratory viral panel AND Presence of infection identified on culture or PCR, but clinical team determines that 
this infection is not the sole cause of the underlying lung injury OR the minimum 
criteria to rule out pulmonary infection are not met (or testing not performed) and 
clinical team determines that this infection is not the sole cause of the underlying lung 
injury AND
A negative influenza PCR or rapid test, if local 
epidemiology supports influenza testing AND
Negative results on testing for all other clinically 
indicated respiratory infectious diseases (e.g., urine 
antigen for Streptococcus pneumoniae and legionella 
species, sputum culture in the presence of productive 
cough, bronchoalveolar-lavage culture if performed, 
blood culture, and HIV-related opportunistic 
respiratory infections if appropriate) AND
No evidence in medical record of alternative 
plausible diagnoses (e.g., cardiac, rheumatologic, or 
neoplastic process)
No evidence in medical record of alternative plausible diagnoses (e.g., cardiac, 
rheumatologic, or neoplastic process).
*
EVALI denotes electronic-cigarette, or vaping, product use-associated lung injury, HIV human immunodeficiency virus, and PCR polymerase 
chain reaction.
†
This criterion is defined as the use of an electronic device (e.g., electronic nicotine-delivery system, e-cigarette, vaporizer, or other device) or 
dabbing to inhale substances (e.g., nicotine, marijuana, tetrahydrocannabinol [THC], THC concentrates, cannabidiol, synthetic cannabinoids, 
flavorings, and other substances).
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